

SIX SIMPLE STEPS TO SUBMITTING A REFERRAL
1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name _____ Address _____ City, State, ZIP _____

Preferred Contact Methods _____ Phone (to primary # provided below) _____ Text (to cell # provided below) _____ Email (to email provided below) _____

Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone _____ Alternate Phone _____ Date of Birth _____ Gender _____ Male _____ Female _____

Email _____ Last Four of SSN _____ Primary Language _____

2 PRESCRIBER INFORMATION

Prescriber's Name _____ State License Number _____

NPI Number _____ DEA Number _____ Group or Hospital _____

Address _____ City, State, ZIP _____

Phone _____ Fax _____ Contact Person _____ Contact's Phone _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date _____ Ship to _____ Patient _____ Office _____ Other _____

Diagnosis (ICD-10):

B17.10 Acute Hepatitis C without hepatic coma _____ B17.11 Acute Hepatitis C with hepatic coma _____

B18.2 Chronic Hepatitis C _____ B19.20 Unspecified Viral Hepatitis C without hepatic coma _____

B20 HIV _____ Other Code: _____ Description _____

For additional ICD-10 information, please visit [Linden Retail Specialty Pharmacy Professionals Website](#)

Patient Clinical Information:

Allergies _____ Weight _____ lb/kg _____ Height _____ in/cm

HCV Genotype: 1a 1b 1 2 3 4 5 6 AND _____ No Cirrhosis _____ Compensated Cirrhosis _____ Decompensated Cirrhosis _____

Is patient: Naïve Partial Responder Non-Responder Relapser; Last Date of Therapy _____ Product Name(s): _____

Is patient currently on Hepatitis C Virus therapy? No Yes Therapy Start Date: _____ Product Name(s): _____

Is patient post-liver transplant? Yes No For Zepatier™ genotype 1a patients, NS5A polymorphism present? Yes No

Nursing:

Specialty pharmacy to coordinate injection training/home health nurse visit as necessary? Yes No

Site of Care: MD Office Infusion Clinic Outpatient Health Home Health

Injection training not necessary. Date training occurred: _____

Reason MD office training patient Pt already independent Referred by MD to alternate trainer

5 PRESCRIPTION INFORMATION

MEDICATIONS	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Daklinza (daclatasvir)	30 mg tablets 60 mg tablets 90 mg tablets	Take one 60 mg tablet PO once a day. Take one 90 mg tablet PO once a day. Other:	Quantity: 28-day supply Refills: 12 weeks Other
Eplusa (sofosbuvir/velpatasvir)	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir	Take on tablet once daily.	Quantity: Refills:

 Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED _____ DATE _____ DISPENSE AS WRITTEN _____ DATE _____

 The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize **Linden Retail Specialty** and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

 Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty** and/or one of its affiliates.

Medication F - Z Hepatitis C Enrollment Form

(Harvoni®, Mavyret™, Pegasys®, Pegintron®, Ribavirin, Ribasphere®,
Sovaldi®, Technivie™, Viekira Pak™, Viekira XR, Vosevi™, Zepatier)

Please complete Patient and Prescriber Information

Patient Name

Patient Date of Birth

Prescriber Name

Prescriber Phone

5 PRESCRIPTION INFORMATION

MEDICATIONS	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
Harvoni (ledipasvir/ sofosbuvir)	Fixed-dose combination tablet of 90 mg ledipasvir / 400 mg sofosbuvir	Take PO once daily with or without food. Do not take within 4 hours antacids.	Quantity: 28-day supply Refills: 8 weeks 12 weeks 24 weeks
Mavyret (glecaprevir and pibrentasvir)	Fixed-dose combination tablet of 100 mg glecaprevir and 40mg pibrentasvir	Take three tablets PO once a day with food.	Quantity: 28-day supply Refills: 8 weeks 12 weeks Other
Pegasys (peginterferon alfa-2a)	180 mcg / 0.5 mL ProClick™ Autoinjector Other:	Inject 180 mcg SC once a week as directed. Other:	Quantity: Refills:
Pegintron (peginterferon alfa-2b)	120 mcg REDIPEN® 150 mcg REDIPEN Other:	Inject mcg SC weekly. Other:	Quantity: Refills:
Ribavirin	200 mg tablets 200 mg capsules	Take tabs/caps PO q am and tabs/caps q pm for a total of mg daily with food.	Quantity: Refills:
Ribasphere RibaPak® (ribavirin)	600 / 600 mg 600 / 400 mg 400 / 400 mg 200 / 400 mg	Take mg PO q am and mg q pm for a total of mg daily with food.	Quantity: Refills:
Sovaldi (sofosbuvir)	400 mg tablets	Take one 400 mg tablet PO once a day.	Quantity: 28-day supply Refills:
Technivie (ombitasvir/paritaprevir/ ritonavir)	Fixed dose combination tablet of ombitasvir / paritaprevir / ritonavir 12.5 mg / 75 mg / 50 mg	Take two tablets once daily in the morning.	Quantity: 28-day supply Refills: 12 weeks
Viekira Pak (ombitasvir/paritaprevir/ ritonavir tabs and dasabuvir tabs)	Copackaged ombitasvir / partiaprevir / ritonavir 12.5 mg / 75 mg / 50 mg and dasabuvir 250 mg	Take 2 pink tablets (ombitasvir, paritaprevir, ritonavir) once daily (morning) and 1 beige tablet (dasabuvir) twice daily (morning and evening) with meals.	Quantity: 28-day supply Refills: 12 weeks 24 weeks
Viekira XR (dasabuvir, ombitasvir, paritaprevir, ritonavir)	Dasabuvir / ombitasvir / partiaprevir / ritonavir 12.5 mg / 75 mg / 50 mg and dasabuvir 250 mg	Take three tablets PO once a day with food.	Quantity: 28-day supply Refills: 12 weeks 24 weeks
Vosevi (sofosbuvir, velpatasvir, and voxilaprevir)	Fixed-dose combination tablet of 400 mg sofosbuvir / 100 mg velpatasvir/100 mg voxilaprevir	Take one tablet PO once a day with food.	Quantity: 28-day supply Refills: 12 weeks Other
Zepatier (elbasvir/grazoprevir)	Fixed dose combination tablet of 50 mg elbasvir / 100 mg grazoprevir	Take one tablet once daily with or without food.	Quantity: 28-day supply Refills: 12 weeks 16 weeks

Patient is interested in patient support programs

Ancillary supplies and kits provided as needed for administration

STAMP SIGNATURE NOT ALLOWED

6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED

DATE

DISPENSE AS WRITTEN

DATE

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing below, I hereby authorize **Linden Retail Specialty** and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with **Linden Retail Specialty** and/or one of its affiliates.

©2019 **Linden Retail Specialty** and/or one of its affiliates. 75-38495B 100818